Structure–function study of cathelicidin-derived bovine antimicrobial peptide BMAP-28: Design of its cell-selective analogs by amino acid substitutions in the heptad repeat sequences  by Ahmad, Aqeel et al.
Biochimica et Biophysica Acta 1788 (2009) 2411–2420
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemStructure–function study of cathelicidin-derived bovine antimicrobial peptide
BMAP-28: Design of its cell-selective analogs by amino acid substitutions in the
heptad repeat sequences☆
Aqeel Ahmad 1, Neeta Asthana 1, Sarfuddin Azmi, Raghvendra M. Srivastava, Brijesh K. Pandey,
Vikas Yadav, Jimut Kanti Ghosh ⁎
Molecular and Structural Biology Division, Central Drug Research Institute, CSIR, Lucknow-226001, IndiaAbbreviations: FITC, ﬂuorescin isothiocyanate; hRB
phosphate buffered saline (pH 7.4); Rho, tetra-meth
iodide; CFU, colony forming units
☆ This is CDRI communication no. 7697.
⁎ Corresponding author. Tel.: +91 522 2612411 18, ex
E-mail address: jighosh@yahoo.com (J.K. Ghosh).
1 These authors have contributed equally to this work
0005-2736/$ – see front matter © 2009 Elsevier B.V. A
doi:10.1016/j.bbamem.2009.08.021a b s t r a c ta r t i c l e i n f oArticle history:
Received 29 April 2009
Received in revised form 24 August 2009
Accepted 25 August 2009
Available online 6 September 2009
Keywords:
Antimicrobial peptide
Antimicrobial and toxic activity
Peptide membrane interaction
Leucine zipper motif
Localization of antimicrobial peptides onto
bacterial and mammalian cellsAlthough BMAP-28 is a potent cathelicidin-derived bovine antimicrobial peptide, its cytotoxic activity
against the human and other mammalian cells is of concern for converting it into a novel antimicrobial drug.
We have identiﬁed a short leucine and isoleucine zipper sequences at the N- and C-terminals of BMAP-28,
respectively. To understand the possible role of these structural elements in BMAP-28, a number of alanine-
substituted analogs were designed, synthesized and characterized along with the wild-type peptide. The
substitution of amino acids at single or multiple ‘a’ position(s) of these structural motifs by alanine showed
signiﬁcant effects on the cytotoxic activity of the molecule on the human red blood cells (hRBCs) and 3T3
cells without showing much effects on their MIC values against the selected bacteria. BMAP-28 and all its
analogs depolarized the Escherichia coli cells with almost equal efﬁcacy. In contrast, the alanine-substituted
analogs of BMAP-28 depolarized hRBCs much less efﬁciently than the parent molecule. Results further
showed that BMAP-28 assembled appreciably onto the live E. coli and hRBC. However, the selected less toxic
analogs of BMAP-28 although assembled as good as the parent molecule onto the live E. coli cells, their
assembly onto the live mammalian hRBCs was much weaker as compared to that of the wild-type molecule.
Looking at the remarkable similarity with the data presented in our previous work on melittin, it appears
that probably the heptad repeat sequence possesses a general role in maintaining the cytotoxicity of the
antimicrobial peptides against the mammalian cells and assembly therein.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Cathelicidins are a group of rapidly growing and structurally diverse
antimicrobial peptides found in several mammalian species [1–6] that
include humans, monkeys, horses, cows, sheeps, goats and guinea pigs.
Cathelicidins contain a highly conserved N-terminal domain called
cathelin and a C-terminal domain that comprises an antimicrobial
peptide [7–12]. Unlikemost of the classical antibiotics,which are built in
a stepwise manner through complex enzymatic reactions, these
cathelicidin-derived antimicrobial peptides are made from gene-
encoded precursors from which the mature peptides are derived by
the sequential removal of the signal peptide and the extended pro-
sequences [13,14]. Most cathelicidins are differentially expressed in a
variety of tissues and exhibit broad-spectrum antimicrobial activity
against several Gram-negative and Gram-positive bacteria, fungi,C, human red blood cell; PBS,
yl rhodamine; PI, propidium
t. 4282; fax: +91 522 2623405.
.
ll rights reserved.protozoa and enveloped viruses as well as can kill tumor cells [2,6,15].
Moreover, cathelicidin-derived antimicrobial peptides can bind and
neutralize endotoxin and induce chemotaxis of neutrophils, T cells and
monocytes [16]. The role of cathelicidin antimicrobial gene family
against cutaneous infection in mouse model has been demonstrated
recently [17], which suggest that cathelicidins are important native
components of innate host defense in mice.
Potent antimicrobial activity of cathelicidin-derived peptides
against a variety of microorganisms, sometimes even at physiological
or elevated salt concentration, makes them good candidates for the
development of novel antimicrobial drug [6,18]. Furthermore, the
absence of disulﬁde bonds makes them easier to synthesize and thus
adds to the advantages of these molecules.
Among the cathelicidin-derived antimicrobial peptides, BMAP-28
has been studied in detail [19,20]. BMAP-28 has been reported to be
active against Gram-positive and Gram-negative bacteria and fungi.
Although BMAP-28 is a potent antimicrobial peptide, its cytotoxic
activity against the human and othermammalian cells is amajor barrier
for transforming it into a novel antimicrobial drug. In fact unwanted
cytotoxicity of the antimicrobial peptides in general is a major concern
for the development of new drugs from these molecules. Numerous
efforts are going on by either converting the natural peptides into their
Table 1
Amino acid sequences of BMAP-28 and its analogs.
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[23,24] or peptidomimetic [25–27]with selective activity. Therefore, we
decided to understand the molecular basis of its cytotoxic and
antibacterial activities against different mammalian cells and bacteria
and ﬁnd out how to reduce its cytotoxic activities. Recently, it has been
demonstrated that a leucine zipper motif in melittin plays a crucial role
inmaintaining its toxic activity against human red blood cells but not its
antibacterial activity [28]. However, it is not known whether this
sequence elementhas a similar role in other antimicrobial peptides also.
After looking at the sequence, we identiﬁed a short leucine and iso-
leucine zipper sequences at the N- and C-terminals of BMAP-28,
respectively. We intended to determine the possible role of these
structural motifs of BMAP-28 in determining its cytotoxic and
antibacterial activities against the mammalian cells and microorgan-
isms, respectively. In combinationwithour previous results our purpose
was to have a general understanding about the role of this motif in the
antimicrobial peptide family too. For this purpose a number of alanine-
substituted analogs of BMAP-28 were designed, synthesized and
characterized along with the wild-type peptide. To understand the
basis of their antibacterial and cytotoxic activities, detailed interactions
of the wild-type and mutated peptides including their binding,
localization and assembly onto different cells were studied.
2. Materials and methods
2.1. Materials
Rink amide MBHA resin (loading capacity, 0.63 mmol/g) and all
the N-α Fmoc and side chain protected amino acids were purchased
from Novabiochem, Switzerland. Coupling and other reagents for
solid phase peptide syntheses and cleavage of peptides from the resin
as reported before [28–30] were purchased either from Sigma, India
or from reputed local companies. Acetonitrile (HPLC grade) was
procured from Merck, India while triﬂuoroacetic acid (TFA) was
purchased from Sigma, India. Egg phosphatidylcholine (PC) and egg
phosphatidylglycerol (PG) were procured from Northern Lipids, Inc.,
Canada while cholesterol (Chol) was purchased from Sigma. Tetra-
methylrhodamine succinimidyl ester (Rho) and NBD (4-ﬂuoro-7-
nitrobenz-2-oxa-1,3-diazole)-ﬂuoride were purchased from Molecu-
lar Probes (Eugene, OR). Rests of the reagents were of analytical grade
and procured locally; buffers were prepared in milli Q water.
2.2. Peptide synthesis, their ﬂuorescent labeling and puriﬁcation
Stepwise solid phase syntheses of all the peptides, their labeling at
the N-terminus by a ﬂuorescent probe, cleavage of the peptides from
the resins and puriﬁcation by reverse phase HPLC were achieved by
standard procedures as described before [28,29,31]. The puriﬁed
peptides were ∼95% homogeneous and experimental molecular mass
of the peptides, detected by MALDI-TOF analysis, corresponded very
close to the desired values. The concentrations of the peptides were
determined by measuring their absorbance at 280 nm in 6 M
guanidine hydrochloride with the help of tryptophan extinction
coefﬁcients of 5690.
2.3. Hemolytic activity assay
Hemolytic activity of these peptides was assayed against fresh
hRBCs that were collected in the presence of an anti-coagulant from a
healthy volunteer by a standard procedure [21,28,30] as reported
earlier with a ﬁnal concentration of the hRBCs of 6% (v/v) in PBS. Each
of the peptides, dissolved in water, was added to the suspension of red
blood cells (6% v/v) in PBS to the ﬁnal volume of 200 μl from their
respective stock solutions in varying volumes in order to achieve their
desired concentrations and incubated at 37 °C for 35 min. The volume
of the added peptide was adjusted with volume of PBS so that totalvolume of the peptide and hRBC suspensionwas maintained to 200 μl.
The hemolytic activity of the peptides was measured by the release of
hemoglobin from hRBCs in the presence of the peptides as described
earlier [21,28,30].
2.4. MTT assay
MTT assay was done to check the toxic activity of the peptides
against 3T3 cells by a standard procedure as described earlier [32].
Cells (10,000 per well) were seeded in 96-well plates and overnight
incubation was done in CO2 incubator for adherence. The complete
media were discarded from the plate and incomplete media were
added. After that, different concentration of peptides were added and
incubated for 2 h. Now 10 μl of MTT (concentration, 5mg/ml) solution
were added in each well and again incubated for 3 h. Incomplete
media were discarded from 96-well plates and 200 μl of DMSO were
added in each well to dissolve the crystal. The well in which no
peptide was added was considered as the control cells of 100%
viability. Readings of these samples were taken at 550 nm by ELISA
reader [32]. The viability of the peptide-treated cells was calculated
with respect to the control cells of 100% viability.
2.5. Antibacterial activity assay of the peptides
The antibacterial activity of the peptides was assayed in LB
medium under aerobic conditions [21,28] against the selected Gram-
positive and Gram-negative bacteria. Different concentrations of
BMAP-28 and its analogs in water were added in duplicate to 100 μl
(ﬁnal volume) of medium containing the inocula of the test organism
(∼106 CFU) in mid-logarithmic phase of growth. The inhibition of
growth of microorganismswas assessed bymeasuring the absorbance
at 492 nm after an incubation of 18–20 h at 37 °C. The antibacterial
activity of the peptides was expressed in terms of minimal inhibitory
concentration (MIC), the concentration at which 100% inhibition of
microbial growth was observed after 18–20 h of incubation.
2.6. Assay of peptide-induced depolarization of mammalian and
bacterial cell membrane
Peptide-induced depolarization of the hRBC and Escherichia coli
DH5α (mentioned as E. coli in the text whenever this bacterium has
been used) membrane was measured by its efﬁcacy to dissipate the
potential across these cell membranes [33,34]. Fresh human red blood
cells (hRBCs)were collected in the presence of an anti-coagulant from a
healthy volunteer and washed three times in PBS and re-suspended in
the same buffer with a ﬁnal cell density of ∼3.0×107 cells/ml. The
bacteriawere grown at 37 °C until they reached theirmid-log phase and
centrifuged followed by washing with buffer (20 mM glucose,
Table 2
Antibacterial activity of BMAP-28 and its analogs.
Minimal inhibitory concentration (MIC) in μM
Peptides/
antibiotic
Staphylococcus
aureus ATCC 9144
Bacillus subtilis
ATCC 6633
E. coli
DH5α
E. coli ATCC
10536
BMAP-28 3.0±0.4 1.6±0.2 2.4±0.3 2.6±0.6
Mu-1 BMAP-28 3.1±0.5 1.2±0.2 2.5±0.4 2.2±0.3
Mu-2 BMAP-28 3.2±0.5 1.5±0.2 2.6±0.4 2.3±0.4
Mu-3 BMAP-28 3.8±0.6 1.7±0.3 2.7±0.4 2.5±0.4
Mu-4 BMAP-28 3.8±0.6 1.5±0.2 2.7±0.4 2.5±0.4
Mu-5 BMAP-28 3.9±0.6 1.7±0.3 2.6±0.4 2.6±0.4
Tetracycline 1.0±0.2 1.0±0.2 1.2±0.2 1.1±0.2
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∼2×105 CFU/ml) in the similar buffer containing 0.1 M KCL. Both
hRBCs and bacteria were incubated with membrane potential sensitive
probe diS-C3-5 for 1 h. When the ﬂuorescence level (excitation and
emissionwavelengths set at 620 and 670 nm, respectively) of the hRBCs
or bacterial suspension became stable, different amounts of each of the
peptides were added to these suspensions in order to record the
peptide-induced membrane depolarization of either mammalian or
bacterial cell membrane. Membrane depolarization as measured by the
ﬂuorescence recovery (Ft) was deﬁned by the following equation
[33,34]: Ft=[(It− I0)/(If− I0)]×100%, where If, the total ﬂuorescence,
was the ﬂuorescence levels of cell suspensions just after addition of
diS-C3-5; It was the observedﬂuorescence after the addition of a peptide
at a particular concentration either to hRBCs or to E. coli suspensions,
which were already incubated with diS-C3-5 probe for 1 h; and I0 wasFig. 1. Determination of peptide-induced membrane damage of E. coli (E. coli DH5α) cells by
and treated with ∼3.8 μM of BMAP-28, Mu-1 BMAP-28, Mu-2 BMAP-28, Mu-3 BMAP-28, Mthe steady-state ﬂuorescence level of the cell suspensions after 1-h
incubation with the probe.
2.7. Assay of peptide-induced depolarization of zwitterionic and
negatively charged lipid vesicles
The ability of the peptides to destabilize the phospholipid bilayer
was detected by their efﬁcacy to dissipate the diffusion potential
across the membrane. Peptide-induced depolarization of both
zwitterionic PC/Chol (8:1, w/w) and negatively charged PC/PG
(1:1, w/w) lipid vesicles was measured by a standard procedure as
reported earlier [29]. Membrane permeability of the peptide was
detected by the increase in ﬂuorescence, which resulted from the
dissipation of diffusion potential. The peptide-induced dissipation of
diffusion potential was measured in terms of percentage of ﬂuores-
cence recovery (Ft) by the same equation as shown in the previous
section of assay of peptide-induced depolarization of hRBC and
bacteria. Here It was the observed ﬂuorescence after the addition of a
peptide at time t (∼5–8 min after the addition of the peptide), I0 was
the ﬂuorescence after the addition of valinomycin and If was the total
ﬂuorescence observed before the addition of valinomycin. Excitation
and emission wavelengths of diS-C3-5 were the same as above.
2.8. Analysis of peptide-induced membrane damage of 3T3 and E. coli
cells by ﬂow cytometry
Peptide-induced membrane damage was examined by ﬂow cyto-
metry after employing suitable ﬂuorescent probes [35,36]. Peptide-ﬂow cytometric studies. (A–G) PI staining of E. coli cells without any peptide treatment
u-4 BMAP-28 and Mu-5 BMAP-28, respectively.
Fig. 2. The decrease in toxic activity of the BMAP-28 against hRBCs andmurine 3T3 cells
after substitution of leucine/isoleucine residues at ‘a’ positions by alanine. (A) Dose-
dependent hemolytic activity assay of BMAP-28 (a),Mu-1 BMAP-28 (b),Mu-2 BMAP-28
(c),Mu-3 BMAP-28 (d),Mu-4 BMAP-28 (e) andMu-5 BMAP-28 (f). (B) Dose-dependent
MTT assay of themurine 3T3 cells in the presence of all six peptides as mentioned in the
same order marked as (a) to (f).
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the cells with propidium iodide after the treatment with the peptides
at 37 °C for 15 min. These cells were then analyzed by ﬂow cytometry
in the form of dots plot with respect to the control cells, not treated
with any peptide. In order to check themembrane integrity of bacteria
after peptide treatment, the cells at mid-log phase were incubated
with BMAP-28 and its alanine-substituted analogs for 30 min at 37 °C
with constant shaking. The cells were collected by centrifugation,
washed two times with PBS and incubated further with propidium
iodide at 4 °C for 30 min, followed by removal of the unbound dye
through washing with an excess of PBS and re-suspended in buffer.
Peptide-induced damage of bacterial cells was then analyzed by ﬂow
cytometry.
2.9. Fluorescence energy transfer experiments onto the live cells
FRET experiments were performed by utilizing the NBD- and Rho-
labeled peptides onto hRBCs and E. coli cells and analyzed by ﬂow
cytometry as reported [37]. Excitation and emission wavelengths for
NBD were ﬁxed at 488 and 530 nm, respectively, for these ﬂow
cytometric experiments. Equimolar amounts of NBD-labeled peptide
(donor) and Rho-labeled peptides (acceptor)were added to the hRBCs
(∼3×107 cells/ml) and E. coli (∼5×105 CFU/ml) and incubated at
37 °C for 30 and 10min, respectively. Changes inNBDﬂuorescence due
to FRET were determined by comparing the ﬂuorescence of the NBD-
peptide (donor) in the presence of the corresponding Rho-peptide
(acceptor) to that when Rho-peptide was replaced with the unlabeled
peptide.
2.10. Confocal microscopic experiments
Localization of the peptides onto the hRBCs and E. coli DH5α was
determinedwith the help of their Rho-labeled analogs by employing a
Zeiss LSM-510 META confocal microscope with 63X 1.4 NA oil plan
apochromate lens. FreshhRBCs (6% inPBS) asused inpeptides' hemolytic
activity assays were incubated with the same concentration of either
Rho-labeled BMAP-28 or Rho-Mu-3 BMAP-28 and Rho-Mu-5 BMAP-28
for 15 min at 37 °C. Cells were washed and confocal microscopic images
of the live cells were taken with argon ion laser set for Rho-excitation at
457 nm. Setting of the photomultiplier was constant during the whole
experiments.
Localization of these peptides onto E. coli was also examined with
the help of Rho-labeled peptides by employing a confocal microscope.
E. coli (∼106 CFU/ml) in LB medium were incubated in the absence
and presence of Rho-labeled BMAP-28 and its analogs at theirMICs for
0.5 h and then centrifuged, washed and analyzed by the confocal
microscope.
3. Results
3.1. Design of BMAP-28 analogs
BMAP-28 possesses a very interesting amino acid sequence. The N-
and C-terminals of this peptide contain a small stretch of leucine and
isoleucine zipper sequences, respectively (Table 1). It was of our
interest to look into the role of these structural elements in the
bactericidal and cytotoxic activities of BMAP-28 and understanding its
molecular basis. Several analogs were thus designed (Table 1) in
which single, double and even triple leucine/isoleucine residue(s)
was replaced by alanine.
3.2. BMAP-28 and its alanine-substituted analogs exhibited appreciable
antibacterial activity
To look into the effect of substitution of leucine/isoleucineby alanine
at ‘a’ positions of BMAP-28 heptad repeats toward its antibacterialactivity, growth inhibiting activity of the peptides against the selected
Gram-positive and one Gram-negative bacteria of two different strains
in liquid cultures was checked. BMAP-28 is known to exhibit appre-
ciable antimicrobial activity [20]. As shown in Table 2, the designed
analogs of BMAP-28 also showed comparable antibacterial activity as
the wild-type peptide toward these bacteria. The results indicated that
the substitution of amino acids at ‘a’ positions of BMAP-28 heptad
repeats by alanine did not show signiﬁcant effect on the antibacterial
activity of BMAP-28.
In order to further visualize the damage of bacteria by BMAP-28
and its analogs, the effect of the peptides on E. coli was probed by
incubating the peptide-treated cells with the DNA intercalating dye
propidium iodide (PI). Although propidium iodide does not stain the
viable bacteria, it interacts easily with DNA of the cells with damaged
membranes. As shown in Fig. 1, E. coli without any peptide treatment
showed no PI ﬂuorescence. However, an appreciable and similar
number of E. coli cells were stained by PI after theywere treated either
with 3.8 μM of BMAP-28 or its analogs. The data clearly support the
antibacterial activity assay data of the peptides and indicated similar
damage of bacterial cell membrane in the presence of BMAP-28 or its
analogs.
3.3. Substitution of amino acids at ‘a’ positions markedly affected the
cytotoxicity of BMAP-28
Cytotoxic activity of BMAP-28 and its analogs was determined by
measuring their hemolytic activity against the human red blood cells
and by assaying the viability of murine 3T3 cells in the presence of
these peptides. As shown in Fig. 2 BMAP-28 exhibited signiﬁcant
hemolytic activity against the human red blood cells as reported
Fig. 3.Determination of peptide-inducedmembrane damage of murine 3T3 cells by ﬂow cytometric studies. (A–G) PI staining of murine 3T3 cells without any peptide treatment and
treated with ∼3.60 μM of BMAP-28, Mu-1 BMAP-28, Mu-2 BMAP-28, Mu-3 BMAP-28, Mu-4 BMAP-28 and Mu-5 BMAP-28, respectively.
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‘a’ positions by alanine, cytotoxic activity of BMAP-28 decreased
progressively. Thus BMAP-28 analogs with two and three leucine/
isoleucine substitutions exhibited signiﬁcantly reduced hemolytic
activity. However, the substitution of isoleucine at 20th position by
alanine showed dramatic effect on the hemolytic activity suggesting
the importance of this amino acid and C-terminal isoleucine zipper
motif in maintaining the toxic activity of BMAP-28. Fig. 2B shows the
viability of 3T3 cells as measured by MTT assay. Like human red blood
cells, the lowest number of viable cells was observed in the presence of
BMAP-28 and the viability of cells increased progressively with the
substitution of leucine/isoleucine by alanine at ‘a’ positions of its
heptad. MTT assay also showed that in the presence of Mu-3 BMAP-28
in which an isoleucine at position 20 was replaced by a single alanine
residue, the number of viable 3T3 cells increased signiﬁcantly as
compared to the other single alanine-substituted analogs, which was
also observed in case of hemolytic activity assay of the peptides. Thus
the results altogether suggested the role of the heptad repeat sequence
in maintaining the cytotoxicity of BMAP-28.
In order to further look into the cytotoxic activity of BMAP-28 and
its analogs propidium iodide staining of 3T3 cells was performed after
the cells were treated with these peptides. Fig. 3 shows the maximum
number of PI-stained cells when they were treated with BMAP-28.
However, the number of PI-stained cells decreased signiﬁcantly when
BMAP-28 was replaced by its analogs. The results further indicated
that the ability of BMAP-28 to damage the organization of 3T3 cell
membrane decreased appreciably in its alanine-substituted analogs.
Thus the results showed that the analogs of BMAP-28 exhibited
contrasting lytic activity towards the bacteria and mammalian cells.3.4. BMAP-28 analogs depolarized the hRBC cells and bacteria to a
different extent
In order to understand the basis of contrasting cytotoxic activity of
the analogs of BMAP-28 against the mammalian cells and bacteria,
peptide-induced depolarization of hRBCs and E. coli was measured in
the presence of BMAP-28 and its analogs as well. The results showed
that BMAP-28 and its analogs induced appreciable and almost similar
permeability in E. coli cell membrane as evidenced by comparable
ﬂuorescence recovery at certain peptide concentration (Fig. 4A).
However, contrasting results were obtained when peptide-induced
permeability of hRBC membrane was measured. As shown in Fig. 4B,
BMAP-28 induced the highest permeability among these peptides in
hRBCs. However, with substitution of leucine/isoleucine at ‘a’
positions of BMAP-28 heptad, peptide-induced permeability of
hRBCs decreased progressively. Altogether, the results showed that
although BMAP-28 and its analogs depolarized bacterial membrane
with almost similar efﬁciency, the designed analogs of BMAP-28
induced gradually lower permeability in human red blood cells with
substitution of leucine/isoleucine by alanine residues as compared to
the wild-type peptide.
3.5. Differences between BMAP-28 and its analogs in permeabilizing the
zwitterionic lipid vesicles but not in negatively charged lipid vesicles
Lipid vesicles with zwitterionic (like PC/Chol) and negatively
charged lipids (like PE/PG or PC/PG) are often employed to mimic the
eukaryotic and prokaryotic cell membrane, respectively. Therefore, in
order to understand the basis of BMAP-28 and its analog-induced
Fig. 5. Permeabilization of zwitterionic and negatively charged lipid vesicles by BMAP-
28 and its analogs as studied by the dissipation of diffusion potentials induced by the
individual peptides. (A and B) Plots of ﬂuorescence recovery induced by BMAP-28 and
its analogs in PC/Chol and PC/PG lipid vesicles, respectively. Solid square, BMAP-28;
open square, Mu-1 BMAP-28; solid circle, Mu-2 BMAP-28; open circle, Mu-3 BMAP-28;
solid triangle, Mu-4 BMAP-28; open triangle, Mu-5 BMAP-28. Concentration of PC/Chol
and PC/PG lipid vesicles was 68 μM.
Fig. 4. Dose-dependent peptide-induced transmembrane depolarization of E. coli and
hRBC. (A and B) Plots of the percentage of ﬂuorescence recovery, which is a measure of
transmembrane depolarization, vs. peptide concentration in μM of E. coli and hRBCs,
respectively. Solid square, BMAP-28; open square, Mu-1 BMAP-28; solid circle, Mu-2
BMAP-28; open circle, Mu-3 BMAP-28; solid triangle, Mu-4 BMAP-28; open triangle,
Mu-5 BMAP-28.
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zwitterionic PC/Chol and negatively charged PC/PG in the presence
of these peptides was examined by standard procedure as included in
Materials and methods. The ability of BMAP-28 and its analogs to
permeabilize a particular kind of lipid vesicles was determined by
measuring the percentage of ﬂuorescence recovery induced by them
in lipid vesicles at different peptide concentrations. Fig. 5A shows the
dose dependent percentage of ﬂuorescence recovery induced by
BMAP-28 and its analogs in PC/Chol lipid vesicles. The data clearly
indicated that wild-type BMAP-28 appreciably permeabilized PC/Chol
vesicles. However, with alanine substitution BMAP-28 progressively
lost its ability to depolarize the zwitterionic lipid vesicles as evidenced
by the reduced ﬂuorescence recovery in the presence of alanine-
substituted BMAP-28 analogs. Interestingly, contrasting results were
observed when the permeability of negatively charged PC/PG lipid
vesicles was measured in the presence of these peptides. As evident
from the plot of percentage of ﬂuorescence recovery vs. peptide
concentrations (Fig. 5B), BMAP-28 and its analogs possess signiﬁcant
and almost similar efﬁcacy to permeabilize the PC/PG lipid vesicles.
Altogether the data indicated toward the contrasting effect of
substitution of leucine and isoleucine residues by alanine in the ‘a’
position(s) of BMAP-28 heptad in permeabilizing zwitterionic and
negatively charged lipid vesicles.
3.6. Substitution of amino acids at ‘a’ positions of BMAP-28 heptads
affects its localization onto the hRBC cells but not to E. coli
It was investigated how the substitution of amino acids in the
leucine or isoleucine zipper sequences of BMAP-28 inﬂuences the
localization andbinding of the peptides onto the bacteria andmamma-
lian cells by confocal microscopic technique, employing Rho-labeledversions of the peptides. As a representative of bacteria and mam-
malian cells, experiments were performed with E. coli and hRBCs,
respectively. BMAP-28 and its selected analogs internalized into E. coli
cells with almost similar efﬁcacy as evident from their bright red
ﬂuorescence onto these bacteria. Moreover, confocal microscopic
images (both transmission and ﬂuorescence) of E. coli treated with
Rho-labeled either BMAP-28 or its selected analogs showed a damage
of cell membrane and morphology of bacteria. The results indicated
that probably these peptides primarily target the membrane of
bacteria in order to exhibit their antibacterial activity. On the other
hand, BMAP-28 bound and distributed strongly onto the hRBCs as
evidenced by the intense red ﬂuorescence onto these cells. However,
the selected less toxic or non-toxic analogs were distributed much
weakly onto these cells. As shown in Fig. 6, following the treatment of
Rho-labeled BMAP-28 a signiﬁcant damage of the hRBCs was very
prominent which progressively decreased when the hRBCs were
treated with Rho-labeled Mu-3 and Mu-5 BMAP-28, respectively.
Furthermore, the images of the confocal microscopic studies indicated
that Rho-labeling did not affect the ability of BMAP-28 and its analogs
to interact with this bacterium or hRBCs. Taken together the results in
the confocal microscopic studies suggested that substitution of amino
acids at ‘a’ positions of BMAP-28 heptads affected its localization or
binding only onto the hRBCs but not onto E. coli.
3.7. Differences in assembly of BMAP-28 and its analogs in mammalian
cells but not in bacteria
The heptad repeat sequences with leucine and isoleucine zipper
motifs are known to assist in the assembly of the proteins andpeptides.
Fig. 6. Examination of localization of the Rho-labeled BMAP-28, and its analogs (Rho-labeled Mu-3 BMAP-28 and Rho-labeled Mu-5 BMAP-28) onto hRBCs and E. coli DH5α by
confocal microscopy. Each cell type has been marked on top of the images and Rho-labeled peptides, BMAP-28; Mu-3 BMAP-28 (in short Mut-3) and Rho-labeled Mu-5 BMAP-28
(in short Mut-5) that have been used to treat the cells are shown on the left hand side. For each of the peptide treatment, ﬂuorescence and DIC images of each cell type have been
shown. Peptide concentration of each of the Rho-labeled peptides for treatment with hRBCs was ∼6.3 μM whereas for treatment with E. coli was ∼2.4 μM. hRBCs were plated on
poly-L-lysine coated slide and incubated with rhodamine labeled peptides for 15 min in PBS. Afterward cells were ﬁxed in 2% paraformaldehyde (10 min) and washed extensively
with PBS. Before confocal scanning (oil immersion, 63×, crop size: 2) slides were mounted with 80% glycerol containing antifade. Similarly, log phase E. coli were incubated with
rhodamine labeled peptides for 15 min at different concentration (MIC and 70% of MIC) and placed on poly-L-lysine coated slides. Afterward cells were ﬁxed with 2%
paraformaldehyde (10 min) and washed extensively. Before confocal scanning (oil immersion, 63×, crop size: 2) samples were mounted with 80% glycerol containing antifade.
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or isoleucine at ‘a’ positions inﬂuences the assembly of BMAP-28 onto
bacteria andmammalian cells, ﬂuorescence resonance energy transfer
(FRET) experiments were performed onto the live hRBCs and E. coli
with the NBD- and Rho-labeled versions of the peptides by employing
a ﬂow cytometer. Equimolar amounts of NBD-labeled peptides
(Donor) and either unlabeled peptides or Rho-labeled peptides
(acceptor) were incubated with hRBCs at 37 °C. Changes in the
donor ﬂuorescence were compared when the acceptor labeled pep-
tides were replaced by the unlabeled peptides. As shown in Fig. 7,
ﬂuorescence (X-axis value) of hRBCs bound to NBD-BMAP-28
decreased appreciably when unlabeled BMAP-28 was replaced by its
Rho-labeled version. The data indicated a self-association of BMAP-28
molecules onto the hRBCs. Contrastingly, for BMAP-28 analogs (Mu-3
BMAP-28 and Mu-5 BMAP-28) the decrease in NBD-ﬂuorescence in
the presence of corresponding Rho-labeled peptide was signiﬁcantly
less indicating a weaker assembly of these peptide molecules onto
these cells. However, interestingly, while similar experiments were
carried out onto E. coli, ﬂuorescence of the bacteria bound to NBD-
labeled either BMAP-28 or its analogs Mu-3 BMAP-28 and Mu-5
BMAP-28 decreased appreciably when the unlabeled peptides were
replaced by the corresponding Rho-labeled peptides suggesting an
energy transfer events between these NBD- and Rho-labeled peptides.
Thus the data indicated unlike in case of hRBCs, BMAP-28 analogswith
substitution of leucine/isoleucine at ‘a’ positions self-assembled onto
E. coli cells.4. Discussion
The results clearly demonstrated the identiﬁcation of two small
stretches of leucine and isoleucine zipper sequences at the N- and
C-terminal of BMAP-28, which play a pivotal role in maintaining the
cytotoxicity of the molecule but not the antibacterial activity as such.
The substitution of amino acids at the ‘a’ positions of these structural
motifs by alanine showed signiﬁcant effects on the cytotoxic activity
of the molecule against hRBCs and 3T3 cells (Figs. 2 and 3) without
showing much effects on the MIC values of the peptide against the
selected bacteria (Table 2 and Fig. 1).
The molecular basis of the distinct effect of the substitution of
amino acids at ‘a’ positions by alanine on the antibacterial and
cytotoxicity of BMAP-28 was analyzed by studying the direct
interaction of these peptides to the representative bacterial and
mammalian cells.
Since BMAP-28 is a membrane-active peptide, the effect of amino
acid substitution was studied on the ability of the peptides to per-
meabilize the mammalian cells and bacteria. As shown in Fig. 4,
BMAP-28 and all its analogs depolarized the E. coli cells with almost
equal efﬁcacy. In contrast, BMAP-28 depolarized the hRBCs more
efﬁciently than its analogs. The single alanine-substituted analogs of
BMAP-28 (Mu-1 and Mu-2 BMAP-28) depolarized the hRBCs weakly
as compared to the wild-type peptide; the double alanine-substituted
analog (Mu-4 BMAP-28) depolarized signiﬁcantly more weakly
whereas the triple alanine-substituted analog (Mu-5 BMAP-28) was
Fig 7. Detection of self-assembly of BMAP-28, Mu-3 BMAP-28 and Mu-5 BMAP-28 onto
live E. coli and hRBCs by FRET experiments with the help of a ﬂow cytometer. Equimolar
amounts of donor (NBD)-labeled peptides (D) and either the corresponding unlabeled
peptide (U) or acceptor (Rho)-labeled peptide (A) incubated with E. coli (A–C) and
hRBCs (D–F) at 37 °C and then analyzed by ﬂow cytometry. Black (thinner) and gray
(thicker) lines represent (D+U) and (D+A), respectively. (A–C) FRET experiments
onto hRBCs with BMAP-28, Mu-3 BMAP-28 and Mu-5 BMAP-28, respectively, with
∼4.8 μMof each of the peptides. (D–F) FRET experiments onto E. coli cells with the same
peptides at ∼3.0 μM concentration. Events (10,000) were counted for each of these
experiments.
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‘isoleucine’ at position ‘20’ (Mu-3 BMAP-28) considerably reduced the
ability of the peptide to depolarize the mammalian cells, which
probably explains the weaker cytotoxic activity of this BMAP-28
analog as compared to the other single alanine-substituted analogs.
The deletion of C-terminal 10 amino acids was reported to have
drastic effect on the hemolytic activity of BMAP-28 [20]. Thus it was
proposed that the C-terminal hydrophobic amino acids are important
in the toxic activity of BMAP-28. We anticipate that since as a result of
this deletion, a part of the heptad repeat was also deleted, and the
assembly of the molecule was impaired, which resulted in the loss of
toxicity of the molecule. However, our observation on more drastic
effect of single amino acid substitution at the C-terminal than the
corresponding amino acid substitution at the N-terminal supports the
earlier proposal [20] that the C-terminal of BMAP-28 could be more
directly involved with its toxic activity. The analogs of BMAP-28 with
substitution of more leucine/isoleucine residues by alanine induced
progressively reduced permeability in zwitterionic lipid vesicles
(Fig. 5A) as was also observed in this peptide-induced depolarization
of hRBCs (Fig. 4B). However, BMAP-28 and its analogs permeabilized
the negatively charged lipid vesicles to a very similar extent (Fig. 5B),
which was also observed for these peptide-induced depolarization of
E. coli (Fig. 4A). The similarities in the trend of BMAP-28 and its
analog-induced depolarization of mammalian cells and bacteria with
that of peptide-induced permeabilization of zwitterionic and nega-tively charged lipid vesicles may be implicated to an important role of
lipid–peptide interactions in determining the antibacterial and
cytotoxic activity of these peptides.
Consistent with the permeabilization of bacteria and mammalian
cells, BMAP-28 analogs induced damages to the membrane organi-
zation of E. coli cells but induced signiﬁcantly lesser damage to the
membrane organization of representative mammalian 3T3 cells as
indicated by PI staining of the cells following the treatments of these
peptides. The observation of damage of bacterial cell membrane and
cellular morphology on confocal microscope (Fig. 6) indicated that
probably BMAP-28 and its analogs target the cell membrane of these
bacteria in order to show antibacterial activity.
The role of assembly of BMAP-28 and its analogs onto the
mammalian cells and bacteria in determining their cytotoxic and
antibacterial activities was addressed by performing energy transfer
experiments with the donor and acceptor labeled BMAP-28 and its
selected analogs onto hRBCs and E. coli (Fig. 7). Probably, the observed
impaired assembly of BMAP-28 as a result of substitution of leucine/
isoleucine residues by alanine residues onto hRBCs could contribute in
the reduction of permeability of these cells in the presence of BMAP-
28 analogs, which may further result in their reduced cytotoxic
activity against these cells. However, the same amino acid substitu-
tions in BMAP-28 did not show much effects on its assembly onto E.
coli, which could assist in maintaining the similar permeability of the
bacteria in the presence of BMAP-28 and its analogs and thus in their
similar antibacterial activities.
It is not clear how the substitution of leucine/isoleucine at ‘a’
positions by alanine does not inﬂuence the assembly of BMAP-28 in
the bacterial cells. We speculate that the electrostatic interactions
between the positively charged amino acids in the peptides and
negatively charged lipids and polysaccharides present on the cell
surface of bacteria could compensate the loss of side chain interac-
tions as a result of this amino acid substitution. Therefore, despite
substitution of leucine or isoleucine residues by alanine at ‘a’ positions
of the BMAP-28 heptad the peptides assembled onto bacteria.
The most interesting observation of the present study was that the
substitution of leucine or isoleucine residue(s) by alanine residue(s)
signiﬁcantly affected the cytotoxic activity of BMAP-28 without dis-
turbing its antibacterial activity against the selected bacteria much.
The similar results were obtained in our earlier studies with melittin
[28] and a 21-residue novel peptide [30] designed on the basis of
leucine zipper sequence. However, the literature shows a variety of
data as a result of substitution of a hydrophobic residue by alanine.
The molecular basis of all these observations are not fully understood
though the amphipathic properties and their secondary structures
deﬁnitely play a signiﬁcant role in determining their cytotoxic and
antibacterial activities. Substitution of two proline by alanine residues
individually at 5 and 9 positions of 13-residue tritripticin, a
cathelicidin-derived antimicrobial peptide, showed a different effect
on its hemolytic activities though in both the cases to some extent
improvement in antibacterial activities against Gram-positive bacteria
was observed [38]. While the substitution of proline at 5th position by
alanine reduced the hemolytic activity to the one third of tritripticin,
the other analog after substitution of proline at 9th position by alanine
exhibited similar hemolytic activity to the parent peptide suggesting
that the same amino acid at two different positions may not have the
same crucial role on the toxicity of the peptide. Though amphipathic
properties are important for determining both the hemolytic and
antibacterial activities of a peptide, proline to alanine substitution at
5th position showed contrasting inﬂuence on its antibacterial and
hemolytic activities indicating that probably sometimes these two
properties are determined by different parameters. The substitution
of three tryptophan residues of tritripticin by alanine signiﬁcantly
reduced its antibacterial and hemolytic activity [39]. On the other
hand, the analog after substitution of three proline residues in
tryptophan rich peptide indolicidin showed comparable antibacterial
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enhanced hemolytic activity [40]. Another study indicated apprecia-
bly enhanced activity of this analog against the Gram-positive bacteria
[41]. Probably, a reduction or enhancement in amphipathic properties
depending on the nature of these amino acid substitutions in
tritripticin/indolicidin plays a crucial role.
Probably, the effect of substitution of a hydrophobic amino acid by
alanine in a shorter peptide (∼15 residue) and larger peptide (∼25
residue)may not be the same. For example, the substitution ofmost of
the hydrophobic residues like leucine, isoleucine and valine indivi-
dually by alanine in 33-mer βpep-25 resulted in an increase in its
antibacterial properties against Gram-negative bacteria Pseudomonas
aeruginosa and E. coli [42]. None of these analogs was hemolytic like
the wild-type peptide. In order to maintain the antibacterial activity
for these peptides probably there is a threshold level of cationicity,
hydrophobicity and amphipathicity. These threshold levels could
depend largely on the length of the peptide and vary from peptide to
peptide depending on their amino acid sequences. Both too much or
too less numbers of either of the hydrophobic or cationic residues are
not conducive for the antibacterial activity of a peptide. Therefore,
even the substitution of a more hydrophobic residue by alanine could
enhance the bactericidal activity of a peptide. Probably, a larger and
more hydrophobic peptide can withstand the effect of replacement of
more hydrophobic amino acid by alanine in terms of antibacterial
activities. Such amino acid substitutions in shorter peptides may
result in a compromise in bactericidal activity. BMAP-28 is a very
hydrophobic peptide with approximately two thirds of hydrophobic
amino acids and a relatively bigger sizewith 27 residues.We infer that
for these reasons even after replacement of three leucine/isoleucine
residues by alanine not much alteration in antibacterial activity was
observed. Most importantly, the antibacterial activity of alanine-
substituted BMAP-28 analogs was supported by their appreciable
ability to depolarize the selected bacteria and negatively charged lipid
vesicles as well as their localization onto the bacteria which were
comparable to that of the wild-type BMAP-28 peptide.
In contrast to the antibacterial properties, considering the studies on
melittin [28], 21-residue novel leucine zipper peptide [30] and the
present study on BMAP-28 it seems that the substitution of leucine/
isoleucine residue(s) at the ‘a’position(s) of the heptad repeat sequence
by alanine has a special effect on the cytotoxic activity probably
suggesting very crucial roles of the heptad amino acid sequences to
maintain their cytotoxicity. Substitution of leucine residues in the
leucine zipper sequence of melittin by non-natural amino acids as
reported by others [43] also yielded similar results on its cytotoxicity. As
alreadymentioned that the lesser cytotoxic activity of BMAP-28 analogs
was supported by their reduced permeability toward hRBCs andweaker
binding and localization onto these cells.
Looking at the remarkable similarity of the data presented in our
previous work on melittin [28], 21-residue novel leucine zipper based
peptide [30] and the present study on BMAP-28, it appears that a trend
is emerging towards a general role of the heptad repeat sequence in
maintaining cytotoxicity of the antimicrobial peptides against the
mammalian cells. The data presented here also provide a means with
probable molecular basis of designing cell-selective analogs of bovine
cathelicidin-derived antimicrobial peptide BMAP-28 and perhaps of
other peptides also having this structural element.
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